Understanding of the molecular mechanisms by which DNMT3A PWWP-domain mutations are mechanistically heterogeneous is advanced, providing a biochemical framework that contributes to distinct disease phenotypes.
Abstract
DNMT3A is a de novo DNA methyltransferase whose recruitment to chromatin regulates its function. Missense mutations within the chromatin-binding PWWP domain are associated with diverse human disorders, yet how mutations in the same domain produce distinct phenotypes remains unclear. Here we systematically characterise 19 clinically reported mutations in the PWWP domain of DNMT3A that are associated with Heyn-Sproul-Jackson syndrome (HESJAS), paraganglioma (PG) and clonal haematopoiesis (CH). We show that all PWWP-domain mutations associated with HESJAS abolished interaction with H3K36me2 modified nucleosomes, defining this as a consistent biochemical feature of HESJAS. In contrast, mutations from all disease classes differentially altered DNA binding of the PWWP domain, driven by alterations in the net charge of the domain. However, these effects are largely overcome by inclusion of the DNNMT3A1 N-terminal region, which is absent from its embryonic isoform, suggesting that PWWP mutations may differentially affect DNMT3A function through development. Changes in the thermal stability of the isolated PWWP domain mutants did not directly translate into altered stability of full-length DNMT3A1 in cells. We show that HESJAS mutations can affect the intramolecular interaction between the PWWP and adjacent ADD domain, an interaction proposed to contribute to the autoinhibitory function of the ADD domain. However, not all mutations behaved in the same way, suggesting that multiple factors govern the intramolecular autoinhibition of DNMT3A. Together, this study advances our understanding of the molecular mechanisms by which DNMT3A PWWP-domain mutations are mechanistically heterogeneous, providing a biochemical framework that contributes to distinct disease phenotypes. Highlights Mutations in the DNMT3A PWWP domain are associated with disease phenotypes Loss of H3K36me2 binding is a unifying mechanism for HESJAS The N-terminal extension of DNMT3A1 alters isoform DNA binding PWWP mutations modify the interaction with the ADD domain of DNMT3A
This work establishes a framework linking variant-specific defects in nucleosome binding to chromatin-targeting failure and transcriptional dysregulation in RTT.
Li-Qi Yao, Carolina Valderrama-Hincapié, Jia-Rui Song et al.· bioRxiv· 0 citations
Findings show that KDM5-dependent transcriptional regulation cannot be explained by demethylase activity alone and support altered chromatin regulatory interactions as a key mechanism underlying pathogenic KDM5 variants.
Melissa A. Castiglione, Matanel Yheskel, Aubrey A Siebels et al.· G3· 1 citation
Abstract Rett syndrome neurodevelopmental disorder is caused by mutations in the epigenetic regulator MeCP2. While the MeCP2 methyl-CpG binding domain (MBD) is well-characterized, the function of the adjacent intervening domain (ID) remains largely understudied. The ID has been described as a distinct RNA-binding regio...
J. Peter, T. Weiser, L. Niswander et al.· Nucleic Acids Research· 0 citations
Mutations in the DNA methyltransferase 1 (DNMT1) enzyme can lead to neurodegenerative diseases, including autosomal dominant cerebellar ataxia–deafness and neuropathy (ADCA-DN) and hereditary sensory and autonomic neuropathy type 1E (HSAN1E). The impact of these mutations on the structural dynamics of DNMT1 remains lar...
Song Xie, Can Bora Yildiz, Paolo Ruggerone et al.· Journal of Chemical Theory a...· 0 citations
Histone lysine demethylases are mainly known as transcriptional regulators for their demethylase activity, but catalysis-independent functions are increasingly recognized. This work focuses on lysine-specific demethylase 5B (KDM5B), targeting H3K4me3. The canonical functional isoform is PLU-1. A catalytically inactive...
Valeria Manzini, Elena Di Nisio, Alessandro Piana et al.· International Journal of Mol...· 0 citations
Mutations in the epigenetic regulator ASXL1 are common in myeloid malignancies and portend a near-universally poor prognosis. While multiple mechanisms for mutant ASXL1-dependent oncogenesis have been proposed, none have been functionally validated in the context of the human hematopoietic stem cell, where these mutati...
Madison L. Hall, Aliya Quintal, Sonia N. Acharya et al.· Blood· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.